Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Celator nets $41mm through public offering

Executive Summary

Celator Pharmaceuticals Inc. (developing combination cancer drugs) netted $41mm through the public sale of 4.6mm shares (including the overallotment) at $9.50. Some of the proceeds will go towards development, regulatory, manufacturing, and sales activities related to Vyxeos (liposomal cytarabine/daunorubicin) in Phase III for acute myeloid leukemia.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Liposomes
    • Nanotechnology, Chips, etc.
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies